An overview of Middle East respiratory syndrome coronavirus vaccines in preclinical studies.

ABSTRACT:

Introduction

Middle East respiratory syndrome coronavirus (MERS-CoV) causes high mortality in humans. No vaccines are approved for use in humans; therefore, a consistent effort to develop safe and effective MERS vaccines is needed.

Areas covered

This review describes the structure of MERS-CoV and the function of its proteins, summarizes MERS vaccine candidates under preclinical study (based on spike and non-spike structural proteins, inactivated virus, and live-attenuated virus), and highlights potential problems that could prevent these vaccines entering clinical trials. It provides guidance for the development of safe and effective MERS-CoV vaccines.

Expert opinion

Although many MERS-CoV vaccines have been developed, most remain at the preclinical stage. Some vaccin

SUBMITTER: Zhang N 

PROVIDER: S-EPMC7755455 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature